ライフサイエンスコーパス: topical agent

1 e efficaciously reduced by administration of topical agents.

2 d to facilitate hemostasis by application of topical agents.

3 mucus discharge, urgency, and treatment with topical agents.

4 d incident rate compared with treatment with topical agents.

5 racameral antibiotic was more effective than topical agent alone (OR, 0.58; CI, 0.38-0.91).

6 ents with severe psoriasis were treated with topical agents alone.

7 y of imiquimod, 26, which was developed as a topical agent and has been approved for the treatment of

8 Topical agents and botulinum toxin A are recommended for

9 lving genetically modified mice treated with topical agents and human dermatological conditions, such

10 ompound 11 has completed phase 1 trials as a topical agent, and 12 is in phase 3 trials for pemphigus

11 of mechanical fragility, toxicity of various topical agents, and the use of emollients.

12 c approach to therapy should be used wherein topical agents are altered every 6-8 months and technolo

13 roxide, azelaic acid, and/or combinations of topical agents are first-line treatments.

14 n protection) followed by stepwise trials of topical agents (e.g., capsaicin), antiepileptic drugs (e

15 and cats which was directly compared to the topical agents fipronil and imidacloprid, with favorable

16 compounds have the potential to be effective topical agents for treating respiratory inflammatory dis

17 The two topical agents for treatment of BV have differing microb

18 roved as well, with the development of newer topical agents for vitiligo, including topical calcineur

19 Although these topical agents have recently been introduced in commerci

20 rt-term protocols for testing the utility of topical agents in the repair of photoaged skin.

21 l allow physicians to understand the role of topical agents in the treatment of intractable pain synd

22 e findings of the present study suggest that topical agents may effectively reduce N. gonorrhoeae inf

23 For patients with mild psoriasis, topical agents remain the mainstay of treatment, and the

24 versely steroid-sparing approaches including topical agents such as beclomethasone or sirolimus as a

25 Treatment of atopic dermatitis with topical agents such as tacrolimus ointment and phosphodi

26 Topical agents, such as microbicides, that can protect a

27 or nonmelanoma skin cancer (NMSC), including topical agents, surgery, or definitive or adjuvant radia

28 an unmet dermatological need for innovative topical agents that achieve better longterm outcomes wit

29 ndispensable for the testing of vaccines and topical agents that are aimed toward the prevention of h

30 Moreover, topical agents that lower IOP in normotensive mice also

31 owerful and feasible strategy to develop new topical agents that suppress AR.

32 is currently the most frequently prescribed topical agent, though the use of ELA-max, another lidoca

33 Auranofin appears to be a potent and safe topical agent to further investigate for treatment of mi

34 virus, they show promise for development as topical agents to avert sexually transmitted diseases.

35 Therapy includes topical agents to improve moisture and decrease inflamma

36 that retrocyclin-like agents might be useful topical agents to prevent sexually acquired HIV-1 infect

37 ated molecules could serve as prototypes for topical agents to prevent sexually transmitted chlamydia

38 e effects, can potentially be developed into topical agents to prevent skin photocarcinogenesis, part

39 sm used in rinse-off formulations to deliver topical agents to the skin and hair; this process produc

40 Treatments currently available are: topical agents used predominantly for mild disease and f

41 Their unique appeal as nonsteroidal topical agents with good safety profiles has led to thei

42 Combinations of topical agents with systemic agents (oral antibiotics su